The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 09, 2016
Filed:
Jan. 03, 2013
Applicant:
Immunocore Limited, Abingdon, Oxfordshire, GB;
Inventors:
Bent Karsten Jakobsen, Abingdon, GB;
Yi Li, Abingdon, GB;
Steven Mark Dunn, Abingdon, GB;
Peter Eamon Molloy, Abingdon, GB;
Assignees:
Immunocore Limited, Abingdon, GB;
Adaptimmune Limited, Oxford, GB;
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/00 (2006.01); C07H 21/04 (2006.01); C07K 14/705 (2006.01); A61K 47/48 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 47/48276 (2013.01); C07K 14/7051 (2013.01); A61K 38/00 (2013.01);
Abstract
The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a Kof less than or equal to 1 μM and/or an off-rate (k) of 1×10Sor slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.